ALNY - Alnylam Pharmaceuticals, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
85.37
-2.04 (-2.33%)
At close: 4:00PM EDT

85.37 0.00 (0.00%)
After hours: 4:07PM EDT

Stock chart is not supported by your current browser
Previous Close87.41
Open87.33
Bid85.42 x 1100
Ask85.45 x 1100
Day's Range84.67 - 87.33
52 Week Range60.27 - 124.22
Volume328,535
Avg. Volume757,451
Market Cap9.087B
Beta (3Y Monthly)2.44
PE Ratio (TTM)N/A
EPS (TTM)-7.57
Earnings DateMay 1, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est123.72
Trade prices are not sourced from all markets
  • Business Wireyesterday

    Alnylam to Webcast Conference Call Discussing First Quarter 2019 Financial Results

    Alnylam Pharmaceuticals, Inc. (ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the first quarter ending March 31, 2019 on Wednesday, May 1, 2019, before the U.S. financial markets open. To access the call, please dial 800-289-0438 (domestic) or 323-794-2423 (international) five minutes prior to the start time and refer to conference ID 4935120. To access the replay, please dial 888-203-1112 (domestic) or 719-457-0820 (international) and refer to conference ID 4935120.

  • This Is Why You Shouldn’t Count Regeneron Stock Out
    InvestorPlace2 days ago

    This Is Why You Shouldn’t Count Regeneron Stock Out

    For many healthcare stocks, April 2019 has been like tech's December 2018. Just 19% of healthcare issues are above their 50-day moving averages. Blame presidential candidate Bernie Sanders. Or blame the Democratic House, which has been holding hearings on a variety of ideas for cutting drug costs. Congress may end the practice of patent "gaming," in which drug companies make small tweaks to drugs in order to extend patent protection.Source: Shutterstock But whatever Congress does, it shouldn't impact Regeneron Pharmaceuticals (NASDAQ:REGN) to the degree it has -- Regeneron stock has plunged nearly 20% from over $400 per share on April 9 to an April 22 opening price of $333. Regeneron's MethodI have long been a fan of Regeneron stock. While most drug companies tie their futures to specific cures, Regeneron has always been focused on their methods for finding drugs.InvestorPlace - Stock Market News, Stock Advice & Trading TipsThese include Velocisuite, which offers fast manipulation of mouse DNA, and TRAP, a general method for developing enzyme blockers. Methods mean Regeneron's pipeline can be constantly renewed for a variety of conditions, from cancer to pulmonary disease to chronic pain.Methods matter. Methods get companies ahead of trends.Regeneron doesn't just know this in its research strategy but in its investment strategy. This is evidenced by a recent $800 million deal with Alnylam (NASDAQ:ALNY) to work on RNA interference, controlling how genes are expressed by interfering with messenger RNA that turns DNA sequences into traits.If Alnylam were Regeneron's only big bet, I wouldn't be listening to bullish forecasts about it. But it's not. Regeneron has development deals with many other companies, including Sanofi (NASDAQ:SNY) and Bluebird (NASDAQ:BLUE), because its gene manipulation methodology can bring drugs to markets faster. * 10 High-Yielding Dividend Stocks That Won't Wilt By having a drug development methodology and cash to spend with companies with specific therapies in mind, Regeneron investors get the ability to spread their bet across many therapies and approaches. Drugs Out of FashionUnfortunately, that's not how Regeneron is valued. Instead, analysts follow the fate of specific Regeneron cures in the market, acting like competition for a single "blockbuster" is going to sink REGN stock.Right now, this makes REGN stock a great bargain. Regeneron's return on equity is 28%. Its price-to-earnings ratio is below 16, with investors paying $333 for over $21 per share of earnings. That's bargain territory.Regeneron is expected to earn $5.39 per share on revenues of $1.72 billion when it next reports May 7, but it has lately made a habit of beating earnings estimates, often by a lot. Analysts are whispering it might beat estimates this quarter by 14 cents, but in the last quarter, it beat estimates by $1.24, and the current estimates are lower. The Bottom Line on Regeneron StockI take a long-term view on stocks, looking for the leading edge of technology, where the value added to society is greatest.The current decade has been all about the cloud, which has brought enormous amounts of computing power to desktops and even mobile platforms.The next decade will be about using this power to turn DNA into a computer language that can be read and manipulated. A research methodology can act like an old-style PC operating system in this worldThis is not a guarantee of long-term success. It only means a company is playing the new game in the right way. That's what I like about Regeneron stock. It has method amid the madness.Dana Blankenhorn is a financial and technology journalist. He is the author of a new mystery thriller, The Reluctant Detective Finds Her Family, available now at the Amazon Kindle store. Write him at danablankenhorn@gmail.com or follow him on Twitter at @danablankenhorn. As of this writing, he owned shares in REGN. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 7 Tech Stocks With Too Much Risk, Not Enough Upside * 7 Companies That Are Closing the CEO-Worker Wage Gap * 7 Video Game ETFs That Will Make You a Winner Compare Brokers The post This Is Why You Shouldn't Count Regeneron Stock Out appeared first on InvestorPlace.

  • Here is What Hedge Funds Think About Alnylam Pharmaceuticals, Inc. (ALNY)
    Insider Monkey5 days ago

    Here is What Hedge Funds Think About Alnylam Pharmaceuticals, Inc. (ALNY)

    "Market conditions are changing. The continued rise in interest rates suggests we are in the early stages of a bond bear market, which could intensify as central banks withdraw liquidity. The receding tide of liquidity will start to reveal more rocks beyond what has been exposed in emerging markets so far, and the value of […]

  • Alnylam Initiates Phase III ILLUMINATE-B Study on Lumasiran
    Zacks8 days ago

    Alnylam Initiates Phase III ILLUMINATE-B Study on Lumasiran

    Alnylam (ALNY) initiates phase III study on lumasiran and also reports new positive efficacy results from the ongoing phase II open-label extension (OLE) study on the same.

  • Is Alnylam Pharmaceuticals a Buy Now?
    Motley Fool8 days ago

    Is Alnylam Pharmaceuticals a Buy Now?

    Everything's falling into place for the pioneer of RNA interference.

  • Alnylam (ALNY) Reports Phase III ENVISION Data on Givosiran
    Zacks9 days ago

    Alnylam (ALNY) Reports Phase III ENVISION Data on Givosiran

    Alnylam (ALNY) reports complete positive results from the phase III ENVISION study of givosiran for the treatment of acute hepatic porphyria.

  • Business Wire9 days ago

    Alnylam Initiates ILLUMINATE-B Phase 3 Pediatric Study of Lumasiran for the Treatment of Primary Hyperoxaluria Type 1 and Presents New Positive Results from Phase 2 Open-Label Extension Study

    Alnylam Pharmaceuticals, Inc. (ALNY), the leading RNAi therapeutics company, announced today that the Company has initiated ILLUMINATE-B, a global Phase 3 pediatric study of lumasiran, an investigational, subcutaneously administered RNAi therapeutic in development for the treatment of primary hyperoxaluria type 1 (PH1). The study will enroll approximately eight patients with PH1 under six years of age. The primary endpoint is the percent reduction in urinary oxalate from baseline to six months.

  • Business Wire12 days ago

    Alnylam Presents Positive Complete Results from ENVISION Phase 3 Study of Givosiran, an Investigational RNAi Therapeutic for the Treatment of Acute Hepatic Porphyria

    Alnylam Pharmaceuticals, Inc. (ALNY), the leading RNAi therapeutics company, announced today positive complete results from the ENVISION Phase 3 study of givosiran, an investigational RNAi therapeutic targeting aminolevulinic acid synthase 1 (ALAS1) in development for the treatment of acute hepatic porphyria (AHP).

  • 4 Drug/Biotech Stocks Making a Mark in RNAi Therapeutics
    Zacks13 days ago

    4 Drug/Biotech Stocks Making a Mark in RNAi Therapeutics

    We take a look at companies, which have been developing treatments for various diseases using RNAi technology.

  • Biotech Stock Roundup: AMGN's Evenity Earns FDA Approval, Deal Wins & More
    Zacks14 days ago

    Biotech Stock Roundup: AMGN's Evenity Earns FDA Approval, Deal Wins & More

    Key highlights of the past week are new drug approvals, collaborations and pipeline updates.

  • Markit15 days ago

    See what the IHS Markit Score report has to say about Alnylam Pharmaceuticals Inc.

    Alnylam Pharmaceuticals Inc NASDAQ/NGS:ALNYView full report here! Summary * ETFs holding this stock are seeing positive inflows * Bearish sentiment is low * Economic output in this company's sector is expanding Bearish sentimentShort interest | PositiveShort interest is low for ALNY with fewer than 5% of shares on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Money flowETF/Index ownership | NegativeETF activity is negative and may be weakening. The net inflows of $1.16 billion over the last one-month into ETFs that hold ALNY are among the lowest of the last year and appear to be slowing. Economic sentimentPMI by IHS Markit | PositiveAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is strong relative to the trend shown over the past year, and is accelerating. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to score@ihsmarkit.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.

  • Regeneron, Alnylam Extend Collaboration for RNAi Therapeutics
    Zacks15 days ago

    Regeneron, Alnylam Extend Collaboration for RNAi Therapeutics

    Regeneron (REGN) extends collaboration agreement with Alnylam to develop new RNAi therapeutics for diseases of the eye and central nervous system (CNS).

  • Benzinga16 days ago

    Regeneron, Alnylam Strike $1B Collaboration For RNAi-based Therapeutics

    In a biotech tie-up, Regeneron Pharmaceuticals Inc (NASDAQ: REGN) announced a collaboration agreement Monday with Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY). Regeneron and Alnylam said they will exclusively collaborate on discovering, developing and commercializing new RNA interface — or RNAi — therapeutics for a broad range of disease targets expressed in the eye and central nervous system. The companies will also work on therapies for a select number of targets expressed in the liver. The agreement has Regeneron paying $400 million upfront to Alnylam and buying up to $400 million worth of Alnylam stock at $90 per share.

  • Reuters16 days ago

    Regeneron forays into gene-silencing therapies with Alnylam tie-up

    Regeneron Pharmaceuticals Inc said it would invest $800 million in Alnylam Pharmaceuticals Inc to develop treatments for eye and central nervous system diseases using gene-silencing RNA interference (RNAi) technology. Alnylam, which last year won U.S. approval for the first treatment using the Nobel prize-winning technology, has a host of other such therapies in its pipeline for various genetic, cardio-metabolic, liver and eye and central nervous system (CNS) diseases. Regeneron will make a $400 million upfront payment to Alnylam and also purchase 4.44 million of Alnylam common shares at $90 per share.

  • Alnylam trades partner Sanofi for Regeneron in $800M deal
    American City Business Journals16 days ago

    Alnylam trades partner Sanofi for Regeneron in $800M deal

    Cambridge gene therapy firm Alnylam is changing alliances, cutting research ties with longtime partner Sanofi and teaming up with Regeneron on new eye and central nervous system treatments.

  • What Do Analysts Think About Alnylam Pharmaceuticals, Inc.'s (NASDAQ:ALNY) Earnings Trajectory?
    Simply Wall St.16 days ago

    What Do Analysts Think About Alnylam Pharmaceuticals, Inc.'s (NASDAQ:ALNY) Earnings Trajectory?

    Want to participate in a research study? Help shape the future of investing tools and earn a $60 gift card! The latest earnings update Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) released in December 2018 suggested...

  • Business Wire16 days ago

    Alnylam and Regeneron Announce Broad Collaboration to Discover, Develop and Commercialize RNAi Therapeutics Focused on Ocular and Central Nervous System (CNS) Diseases

    Alnylam Pharmaceuticals, Inc. (ALNY), the leading RNAi therapeutics company, and Regeneron Pharmaceuticals, Inc. (REGN), announced today a collaboration to discover, develop and commercialize new RNA interference (RNAi) therapeutics for a broad range of diseases by addressing disease targets expressed in the eye and central nervous system (CNS), in addition to a select number of targets expressed in the liver. Under the terms of the alliance, Alnylam will work exclusively with Regeneron to discover RNAi therapeutics for eye and CNS diseases. Regeneron will lead development and commercialization for all programs targeting eye diseases, with Alnylam entitled to potential milestone and royalty payments.

  • PR Newswire16 days ago

    Regeneron and Alnylam Announce Broad Collaboration to Discover, Develop and Commercialize RNAi Therapeutics Focused on Ocular and Central Nervous System (CNS) Diseases

    Regeneron Pharmaceuticals, Inc. (REGN) and Alnylam Pharmaceuticals, Inc. (ALNY) today announced a collaboration to discover, develop and commercialize new RNA interference (RNAi) therapeutics for a broad range of diseases by addressing disease targets expressed in the eye and central nervous system (CNS), in addition to a select number of targets expressed in the liver. The collaboration will leverage both companies' scientific and technological expertise and will build on Alnylam's recent preclinical data showing potent and highly durable delivery of RNAi therapeutics to achieve target gene silencing in the eye and CNS. Under the terms of the alliance, Alnylam will work exclusively with Regeneron to discover RNAi therapeutics for eye and CNS diseases.

  • Business Wire17 days ago

    Alnylam and Sanofi Conclude Research and Option Phase of 2014 RNAi Therapeutics Collaboration

    Alnylam Pharmaceuticals, Inc. (ALNY), the leading RNAi therapeutics company, announced today that Alnylam and Sanofi have agreed to conclude the research and option phase of the companies’ 2014 RNAi therapeutics alliance in rare genetic diseases. “Our landmark 2014 rare disease alliance with Sanofi resulted in the advancement of three Phase 3 programs – patisiran, vutrisiran, and fitusiran – and the global launch of ONPATTRO, the world’s first RNAi therapeutic.

  • 2 Biotechs With Big Dates in April
    Motley Fool25 days ago

    2 Biotechs With Big Dates in April

    Here's what you need to know about two biotechs that will present trial results that could send their stock prices soaring -- or plummeting.

  • Business Wire28 days ago

    Alnylam to Present Givosiran Phase 3 Data at the European Association for the Study of the Liver (EASL) International Liver Congress™

    Alnylam Pharmaceuticals, Inc. (ALNY), the leading RNAi therapeutics company, announced today that the Company and its collaborators will present at the European Association for the Study of the Liver (EASL) 54th Annual International Liver Congress™, being held April 10-14, 2019 in Vienna, Austria. Presentations include full clinical results from the ENVISION Phase 3 study of givosiran, an investigational RNAi therapeutic targeting aminolevulinic acid synthase 1 (ALAS1) in development for the treatment of acute hepatic porphyria (AHP).

  • Alnylam's (ALNY) Impressive Pipeline Drives Share Price
    Zackslast month

    Alnylam's (ALNY) Impressive Pipeline Drives Share Price

    Alnylam's (ALNY) share price increases on robust performance of pipeline candidates.